 |
Development Pipeline
 |
 |
 |
Description: FG-5009 is FibroGen's low molecular weight (8.5 kDa) recombinant gelatin molecule optimized
for use as a stabilizing component in vaccines and biologics.
Status: FibroGen has successfully completed a safety study of FG-5009 in normal volunteers. Data from this
study will be included in a Master File for use by FibroGen's customers.
|
|
Key:
MAb: monoclonal antibody
HIF: hypoxia-inducible factor
CKD: chronic kidney disease
CIA: chemotherapy-induced anemia
rhCIII: recombinant human collagen type III
rhGelatin: recombinant human gelatin
* 2nd generation compounds (undisclosed) in parallel development
|
|
